"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

Please provide your email address to receive an email when new articles are posted on . In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update. ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in its Phase III trial of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...

Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...

Therapeutic advances have significantly improved leukaemia survival rates, but this progress does not apply to all forms of the disease. Chronic myelomonocytic leukaemia (CMML) remains particularly ...

BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...

Ojas Ranade is your typical talented seventh grader, but what he has experienced so far in his young life is anything but ...